MarketInOut Stock Screener Log In | Sign Up

BridgeBio Pharma Inc

XETRA • Healthcare • Biotechnology • Quote as of 10/30/2026
BridgeBio Pharma Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeXETRA
Market Capitalization12,189 mln
Earnings Date10/28/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-1.64
Likely manipulated

Relative Strength

99 / 100
Top performer

Pre-Tax Margin

-99%
Severely loss-making

Altman Z-Score

-3.24
Deeply distressed

ROA

-61.74
Deeply negative

Business Description

BridgeBio Pharma is a drug development company focused on finding and delivering treatments for people living with genetic diseases. Founded in 2015 and based in Palo Alto, California, the company has several medicines either already on the market or in late-stage testing, targeting conditions that affect the heart, bones, muscles, and other areas driven by inherited genetic changes. BridgeBio works alongside partners such as Bayer, Alexion, Novartis, and Stanford University to advance its research and bring new therapies to patients.

Key Fundamentals

EPS-3.10
ROIC-105
ROA-61.74
EBITDA, mln-454
EV / EBITDA-30.79
EV / EBIT-30.49
Revenue, mln612
EV / Revenue22.84

Quote Details

Last 66.66
Change 2.27 (3.53%)
Open 64.15
Volume 132
Turnover 8,799.12
Average Volume 113.38

Financial Ratios

Pre-Tax Profit Margin-99
Current Ratio1.23
Price / Sales18.90

Financial Strength

Altman Z-Score-3.24
Piotroski F-Score 4 / 9
Beneish M-Score-1.64

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 9.06% 99 / 100   
1 Month 13.87% 94 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog